

Written by Australian Business

VANCOUVER, Oct. 25, 2013 /PRNewswire/ - [Augurex](#) Life Sciences Corp. announced today the expansion of key data related to its innovative 14-3-3eta biomarkers with scheduled presentations next week at the prestigious American College of Rheumatology Annual Meeting, taking place at the San Diego Convention Center, October 25-30, 2013. World-leading investigators will present data, including a late-breaking study, describing 14-3-3eta's clinical utility for rheumatoid arthritis (RA) patient management.

Together with its clinical collaborators, Augurex has presented data at the annual meetings of the American College of Rheumatology and the European League Against Rheumatism over the past 4 years describing its panel of 14-3-3eta blood tests. These measure various aspects and forms of the 14-3-3eta protein and inform RA diagnosis, prognosis and therapy monitoring along the disease course. The field of rheumatology is moving towards [early identification and treatment](#) of RA to improve patient clinical outcomes of this otherwise chronic and debilitating autoimmune disease. The schedule for 14-3-3eta presentations at the San Diego Convention Center is as follows.

Title	Date/Time	Location
91% of Early RA Patients Have Positive Serum 14-3-3eta Auto-Antibodies (Abstract 1786)	Oct 28, 10:30am-11:00am	San Diego Convention Center, Room 281
Serum 14-3-3eta Precedes and Independently Predicts the Development of RA (Abstract 1389)	Oct 28, 10:30am-11:00am	San Diego Convention Center, Room 281
14-3-3eta and its Auto-Antibodies Predict Response to Anti-TNF Therapy (Abstract 1315)	Oct 28, 10:30am-11:00am	San Diego Convention Center, Room 281
Chaperonin Protein 14-3-3eta is a Biomarker for Rheumatoid Arthritis and Bacterial and Fungal Infections	Oct 28, 10:30am-11:00am	San Diego Convention Center, Room 281
Serum 14-3-3eta Marks Early Disease Activity and Predicts Radiographic Progression in Early RA Patients	Oct 28, 10:30am-11:00am	San Diego Convention Center, Room 281

In April 2013, Quest Diagnostics (NYSE: [DGX](#)), the world's leading provider of diagnostic information services, [introduced](#) two lab-developed tests to clinicians and patients in the United States based on an exclusive license agreement with Augurex to the 14-3-3eta marker. The new services aid the early diagnosis of RA, with one test service providing results of 14-3-3eta blood levels, while a comprehensive panel provides results of blood levels of 14-3-3eta as well as the conventional RA markers cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor (RF).

Written by Australian Business

Augurex expects 14-3-3eta to soon be available to clinicians and patients in Canada and other major market countries through regional partnerships with leading diagnostic companies.

SOURCE Augurex Life Sciences Corp.